Response to Pazopanib in Patients With Relapsed OsteosarcomaElete, Kunal R. MS, OMS-II*; Albritton, Karen H. MD†; Akers, Lauren J. DO†; Basha, Riyaz PhD*; Ray, Anish MD†Journal of Pediatric Hematology/Oncology: December 07, 2018 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/MPH.0000000000001375 Clinical and Laboratory Observations: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence prognosis adversely in osteosarcoma. Relapse of osteosarcoma, typically occurring within the first 18 months of therapy, with an incidence rate of 50% is treated with surgery, chemotherapy, and targeted therapy. Here, we discuss 2 patients treated with pazopanib, a multi–tyrosine kinase inhibitor presently approved to treat renal cell carcinoma and soft tissue sarcomas. Case 1 achieved positive response and remains on pazopanib. Case 2 sustained gastrointestinal toxicity requiring suspension of drug, despite achieving stable disease. *University of North Texas Health Science Center, Texas College of Osteopathic Medicine †Cook Children’s Medical Center, Fort Worth, TX This study was conducted as part of the University of North Texas Health Science Center and Cook Children’s Pediatric Research Program (PRP). The authors declare no conflict of interest. Reprints: Anish Ray, MD, 1500 Cooper St., 5th floor, Fort Worth, TX 76104 (e-mail: Anish.Ray@CookChildrens.org). Received August 8, 2018 Accepted October 27, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.